Cited by 965Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 217 of the 218 references it cites were found in a registry or an index.

Combination cancer immunotherapies tailored to the tumour microenvironment

Smyth, Mark J., Ngiow, Shin Foong, Ribas, Antoni, Teng, Michele W. L.·2016·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2015.209

Open this paper in CoChat — free account

Abstract

Evidence suggests that cancer immunotherapy will be a major part of the combination treatment plan for many patients with many cancer types in the near future. There are many types of immune processes involving different antitumour and tumour-promoting leucocytes, and tumour cells use many strategies to evade the immune response. The tumour microenvironment can help determine which immune suppressive pathways become activated to restrain antitumour immunity. This includes immune checkpoint receptors on effector T-cells and myeloid cells, and release of inhibitory cytokines and metabolites. Therapeutic approaches that target these pathways, particularly immune-checkpoint receptors, can induce durable antitumour responses in patients with advanced-stage cancers, including melanoma. Nevertheless, many patients do not have a good response to monotherapy approaches and alternative strategies are required to achieve optimal therapeutic benefit. These strategies include eliminating the bulk of tumour cells to provoke tumour-antigen release and antigen-presenting cell (APC) function, using adjuvants to enhance APC function, and using agents that enhance effector-cell activity. In this Review, we discuss the stratification of the tumour microenvironment according to tumour-infiltrating lymphocytes and PD-L1 expression in the tumour, and how this stratification enables the design of optimal combination cancer therapies tailored to target different tumour microenvironments.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2015.209

Cites

217 of 217 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 retracted

TIGIT predominantly regulates the immune response via regulatory T cells
Kurtuluş, S., Sakuishi, K., Ngiow, S. F., Joller, N., Tan, D. J., Teng, M. W. L., Smyth, M. J., Kuchroo, V. K., & Anderson, A. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81187 · Cited by 558
Self-citation
Retracted
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T. J., Mok, S., Cass, A. A., Haynes, N. M., Kinross, K. M., Yagita∥, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 274
Self-citation
Retracted
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
Kohrt, H. E. K., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F. A., Czerwinski, D. K., Colevas, A. D., Weng, W., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
Retracted
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Kohrt, H. E. K., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Müller, A. M. S., Pachynski, R. K., Czerwinski, D. K., Coutre, S. E., et al. (2010) · Blood · doi:10.1182/blood-2010-08-301945 · Cited by 205
Retracted
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Show all 218 references

Sorted by citations

Items 901–965 of 965

Additional file 4 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303575
Additional file 9 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303590
Additional file 4 of PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
Tian, L., Ma, J., Ma, L., Zheng, B., Liu, L., Song, D., Wang, Y., Zhang, Z., Gao, Q., Song, K., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13279500
Additional file 15 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303563
Additional file 13 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303557
Additional file 2 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303569
Additional file 8 of Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells
Wang, X., Miao, J., Wang, S., Shen, R., Zhang, S., Tian, Y., Li, M., Zhu, D., Yao, A., Bao, W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20130980
Additional file 9 of Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells
Wang, X., Miao, J., Wang, S., Shen, R., Zhang, S., Tian, Y., Li, M., Zhu, D., Yao, A., Bao, W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20130983
Additional file 6 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303581
Additional file 2 of Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR
Zhou, X., Du, J., Wang, H., Chen, C., Jiao, L., Cheng, X., Zhou, X., Chen, S., Gou, S., Zhao, W., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12926163
Additional file 6 of Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells
Wang, X., Miao, J., Wang, S., Shen, R., Zhang, S., Tian, Y., Li, M., Zhu, D., Yao, A., Bao, W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20130974
Additional file 1 of Comprehensive analysis of the prognostic value and immunological role of IDO1 gene in pan-cancer
Lin, K., Wang, Y., Liu, F., You, T., Liu, X., Liu, R., Li, Z., Zhen, C., Zhang, Y., Liu, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26698514
Additional file 1 of 3,3′-Diindolylmethane improves antitumor immune responses of PD-1 blockade via inhibiting myeloid-derived suppressor cells
Sun, Q., Xiao, L., Cui, Z., Yang, Y., Ma, J., Huang, Z., Zhang, J., & Chen, J. (2022) · Figshare · doi:10.6084/m9.figshare.20208254
Additional file 2 of FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion
Zhao, Z., Qin, J., Qian, Y., Huang, C., Liu, X., Wang, N., Li, L., Chao, Y., Tan, B., Zhang, N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25284868
Additional file 1 of Tumor-secreted IFI35 promotes proliferation and cytotoxic activity of CD8+ T cells through PI3K/AKT/mTOR signaling pathway in colorectal cancer
Li, P., Zhou, D., Chen, D., Cheng, Y., Chen, Y., Lin, Z., Zhang, X., Huang, Z., Cai, J., Huang, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26600479
Additional file 2 of Tumor-secreted IFI35 promotes proliferation and cytotoxic activity of CD8+ T cells through PI3K/AKT/mTOR signaling pathway in colorectal cancer
Li, P., Zhou, D., Chen, D., Cheng, Y., Chen, Y., Lin, Z., Zhang, X., Huang, Z., Cai, J., Huang, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26600482
Additional file 2 of PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
Tian, L., Ma, J., Ma, L., Zheng, B., Liu, L., Song, D., Wang, Y., Zhang, Z., Gao, Q., Song, K., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13279494
Additional file 1 of Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Marchetti, P., Botticelli, A., Ascierto, A. P., Curigliano, G., & Giannarelli, D. (2020) · Figshare · doi:10.6084/m9.figshare.13290569
Additional file 3 of PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
Tian, L., Ma, J., Ma, L., Zheng, B., Liu, L., Song, D., Wang, Y., Zhang, Z., Gao, Q., Song, K., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13279497
Additional file 1 of PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
Tian, L., Ma, J., Ma, L., Zheng, B., Liu, L., Song, D., Wang, Y., Zhang, Z., Gao, Q., Song, K., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13279491
Additional file 14 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303560
Additional file 2 of 3,3′-Diindolylmethane improves antitumor immune responses of PD-1 blockade via inhibiting myeloid-derived suppressor cells
Sun, Q., Xiao, L., Cui, Z., Yang, Y., Ma, J., Huang, Z., Zhang, J., & Chen, J. (2022) · Figshare · doi:10.6084/m9.figshare.20208257
Additional file 4 of Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells
Wang, X., Miao, J., Wang, S., Shen, R., Zhang, S., Tian, Y., Li, M., Zhu, D., Yao, A., Bao, W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20130968
Additional file 1 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303566
Additional file 10 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303548
Additional file 5 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303578
Additional file 2 of Comprehensive analysis of the prognostic value and immunological role of IDO1 gene in pan-cancer
Lin, K., Wang, Y., Liu, F., You, T., Liu, X., Liu, R., Li, Z., Zhen, C., Zhang, Y., Liu, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26698517
Additional file 5 of Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells
Wang, X., Miao, J., Wang, S., Shen, R., Zhang, S., Tian, Y., Li, M., Zhu, D., Yao, A., Bao, W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20130971
Additional file 7 of Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells
Wang, X., Miao, J., Wang, S., Shen, R., Zhang, S., Tian, Y., Li, M., Zhu, D., Yao, A., Bao, W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20130977
Additional file 3 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303572
Additional file 1 of FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion
Zhao, Z., Qin, J., Qian, Y., Huang, C., Liu, X., Wang, N., Li, L., Chao, Y., Tan, B., Zhang, N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25284805
Additional file 1 of Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
Yi, M., Niu, M., Zhang, J., Li, S., Zhu, S., Yan, Y., Li, N., Zhou, P., Chu, Q., & Wu, K. (2021) · Figshare · doi:10.6084/m9.figshare.16625383
Additional file 1 of LAG3 blockade coordinates with microwave ablation to promote CD8+ T cell-mediated anti-tumor immunity
Shao, D., Chen, Y., Huang, H., Liu, Y., Chen, J., Zhu, D., Zheng, X., Chen, L., & Jiang, J. (2022) · Figshare · doi:10.6084/m9.figshare.21256956
Additional file 12 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303554
Additional file 3 of Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells
Wang, X., Miao, J., Wang, S., Shen, R., Zhang, S., Tian, Y., Li, M., Zhu, D., Yao, A., Bao, W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20130965
Additional file 8 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303587
Additional file 7 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303584
Additional file 11 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303551
Harnessing the Tumor Microenvironment for Cancer Immunotherapy
Fru, P., Nweke, E. E., & Augustine, T. N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00767-4_183 · Cited by 1
Differential predictive value of baseline tumor size according to PD-L1 expression in advanced NSCLC treated with immune checkpoint inhibitors
Ito, H., Shirasawa, M., Akazawa, Y., Watanabe, A., Furo, T., Nishimura, A., Endo, J., WATANABE, A., Kurata, H., Nakano, M., et al. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.101087
Spatial control of genome editing activity enables localized immunotherapyPreprint
Yang, X., Tong, L., Pan, Y., Huang, J., Yi, Z., He, D., Liu, J., Wang, C., Liang, Y., & Tong, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.14.699490
“Immune checkpoint blockade can elicit durable antitumour responses, yet tumour heterogeneity and adaptive resistance often necessitate combination strategies 15,16,17,18 .”
Dysregulation of ceRNA mechanisms across pan-cancer drives cancer progression towards acquiring metastatic potential
He, D., Sun, R., Shan, X.-Y., Xu, B., Xin, M., Liu, Q., Li, J., Li, H., Zhang, Y., Dai, Y., et al. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102046
Theranostic of neutrophilization nanoparticles
Sun, D., Song, B., Sun, W., Li, A., Gao, Z., & Yu, D. (2026) · Progress in Materials Science · doi:10.1016/j.pmatsci.2026.101699 · Cited by 1
Photoactivated probiotic micro-reactor synchronizes STING/TLRs agonists to spatiotemporally synergize antitumor immunotherapy
Qiu, Y., Liu, Y., Chen, S., Liu, Y., Yu, X., Yang, X., Zhang, Y., & Zhu, Y. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04300-w
Impact of Targeting the Autophagy Related Gene Beclin 1 on the Immune Landscape of Melanoma
Arakelian, T. (2018) · theses.fr (ABES) · doi:10.70675/cd5f1ed6z9100z4dd3zb7fazb0537054f400
A Study on the Role of the Intestinal MAdCAM-1/alpha4beta7 Axis in Tumor Immunosurveillance During PD-1 Blockade
Rauber, C. (2019) · theses.fr (ABES) · doi:10.70675/5fb4cecbz179az43d6z9448zfb2d158b7f02
Role of the BTN3A family of proteins in the recognition mechanism of tumor cells by gamma delta-T cells : characterization of physical and functional interactions goberning BTN3A biology
Roman, J. L. B. (2019) · theses.fr (ABES) · doi:10.70675/0574ed23z15dbz4273z8c00z541d98fed316
L'absence de CD226 caractérise des LT CD8+ hyporépondeurs au TCR et aux fonctions antitumorales défectueuses
Weulersse, M. (2019) · theses.fr (ABES) · doi:10.70675/2a56dbcazd721z44daz9b18z27d6c10e6137
Nouvelles signalisations impliquant les lysines-méthyltransférases SMYD2 et SMYD3 dans le cancer
Roth, G. S. (2020) · theses.fr (ABES) · doi:10.70675/571d2839z5ba2z4041zad5bzc230e5547fe3
Impact du ciblage du domaine de liaison de HIF-1α avec HIF-1β sur le paysage immunitaire du mélanome
Lequeux, A. (2020) · theses.fr (ABES) · doi:10.70675/a29d12dbz79c1z4d37za978z2e2319131c82
Role of the antibiotics on the resistance to antitumor immunotherapy based on anti-PD1 monoclonal antibody
Fidelle, M. (2021) · theses.fr (ABES) · doi:10.70675/2168c5d5zc7cez4351zb678z1a8c9761484f
Role of small molecule-based drugs in cancer immunotherapy
Shah, U., Patel, M., Patel, A., Shah, P., Dwivedi, A. R., & Maheshwari, R. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-41551-7.00014-x
Tumor cell intrinsic mechanisms of immune escape
Sriram, G., Aquib, A., Glassman, R., & Birge, R. B. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02891-3
“Unfortunately, the high expectations have yet to be met, as assets targeting novel I-O targets such as IDO, TIMI-3, ICOS, and TIGIT failed in the clinic; so we are left with only a few incremental combinatorial options to prevent or overcome immune escape [113].”
A Three-Gene Interferon Signature Predicts Sustained Complete Remission in Pediatric AML Patients
Sherif, S., Ali, A., Ibrahim, K., Rinchai, D., Elanbari, M., Kizhakayil, D., Toufiq, M., Vempalli, F. R., Mina, T., Comoli, P., et al. (2026) · Cancers · doi:10.3390/cancers18091423
“The contexture, functional orientation, and intricate interactions of immune cell subsets and tumor cells within the TME can directly influence patients’ treatment response and clinical outcomes [6–8].”
Fungal metabolite-based immunotherapy overcomes tumor-associated macrophage immunosuppression
Hu, J., Ju, X., Deng, B., Tang, K., Yuan, D., Sun, X., Kong, L., Xu, Y., Fu, Z., Koda, S., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102833
Self-citation
Prostate cancer: Tumor microenvironment
Naik, J., Chauhan, S., & Patel (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36783-0.00013-7
Recombinant adenoviruses application for cancer vaccines: from genetic design to clinical translation
Almarghalani, N. A., Ganash, M., Alharbi, M. G., Abualfaraj, T., Alkayyal, A. A., & Mahmoud, A. B. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1824087
Advances in paclitaxel-mediated remodeling of the gastric cancer immune microenvironment and sensitization to immune checkpoint inhibitors via cGAS-STING pathway activation triggered by mtDNA release: challenges and translational perspectives
Wu, C., Sun, Z.-L., & Ye, K. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12570-8
“…sequential or combined strategy of “chemotherapy activates innate immunity, and immune checkpoint blockade reverses adaptive immune suppres-sion” forms the strategic rationale for paclitaxel combined immunotherapy, and is also an important direction for current research on GC immunotherapy [35].”
pH-Responsive liposomes co-delivering a membrane-active peptide and the PI3Kγ inhibitor to reconstruct the tumor microenvironment for enhanced antitumor immunotherapy
Li, C., Li, M., Wu, X., Wu, X., Gao, H., Zhong, X., Yang, X., Hao, F., Li, C., & Wang, Q. (2026) · Biomaterials Science · doi:10.1039/d6bm00678g
Advanced Materials for Biologics Delivery to Brain Tumors
Feng, Y., Cao, Y., Kavallaris, M., Janjua, T. I., & Popat, A. (2026) · Advanced Materials · doi:10.1002/adma.74760
Clinical Efficacy of Tislelizumab Plus Gemcitabine-Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer and Chemoresistance Analysis: A Prospective Pilot Study
He, Y., Peng, X., Jiang, C., Li, J., Li, S., Xiang, X., You, N., Yang, X., Tang, Y., Huang, X., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20711-3
Discordance of PD-L1 expression between primary and paired metastatic non-small cell lung cancer: a systematic review and meta-analysis
Zhang, L., 高逸耀, Wang, X., Gu, Y., Hou, L., & Wang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1942041
“By blocking the PD-1/PD-L1 interaction, ICIs restore and enhance the ability of the immune system to recognize and eliminate cancer cells, thereby producing durable clinical responses and improved survival outcomes (8).”
Isoliquiritigenin in breast cancer therapy: from mechanistic insights to advanced nano-enabled delivery strategies.
Ganesan, K., Gao, Y.-Z., Gao, F., Peng, F., Wang, Z.-Y., Wang, D., Wang, N., Dong, J.-X., & Chen, J.-P. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118559
BindingDB Entry 50010327: Design, synthesis and biological evaluation of 2,5-dimethylfuran-3-carboxylic acid derivatives as potential IDO1 inhibitors.
BindingDB (2021) · UC San Diego · doi:10.7270/q2jm2f4q
BindingDB Entry 50000065: Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.
BindingDB (2019) · UC San Diego · doi:10.7270/q2765hhp

Authors: Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L.
Affiliations: QIMR Berghofer Medical Research Institute (AU)
University of California, Los Angeles (US)
Corresponding author: Teng, Michele W. L.
ORCID: Smyth, Mark J.
Ngiow, Shin Foong
Ribas, Antoni
Teng, Michele W. L.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2015-11-24
Volume: 13
Issue: 3
Pages: 143-158
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2015.209
OpenAlex: W2257916459
Cited by: 944
References: 218
Citations by year: 2026: 28 · 2025: 50 · 2024: 71 · 2023: 82 · 2022: 132 · 2021: 102 · 2020: 134 · 2019: 95 · 2018: 99 · 2017: 89 · 2016: 56 · 2015: 3
FWCI: 8.83
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Amgen
Bristol-Myers Squibb
Kite Pharma
National Cancer Institute (R35CA197633)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: cancer immunotherapy, combination therapy, tumor microenvironment, immune evasion, immune checkpoint receptors, PD-L1, tumor-infiltrating lymphocytes, myeloid cells, inhibitory cytokines, antigen-presenting cells, adjuvants, melanoma
MeSH terms: Adjuvants, Immunologic, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Humans, Immunotherapy, Neoplasms, Signal Transduction, Treatment Outcome, Tumor Escape, Molecular Targeted Therapy, Tumor Microenvironment, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Combination cancer immunotherapies tailored to the tumour microenvironment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks